PMID- 38387134
OWN - NLM
STAT- MEDLINE
DCOM- 20240304
LR  - 20240304
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 172
DP  - 2024 Mar
TI  - Label-free analysis of the beta-hydroxybutyricacid drug on mitochondrial redox 
      states repairment in type 2 diabetic mice by resonance raman scattering.
PG  - 116320
LID - S0753-3322(24)00201-4 [pii]
LID - 10.1016/j.biopha.2024.116320 [doi]
AB  - BACKGROUND: Mitochondrial redox imbalance underlies the pathophysiology of type2 
      diabetes mellitus (T2DM), and is closely related to tissue damage and 
      dysfunction. Studies have shown the beneficial effects of dietary strategies that 
      elevate beta-hydroxybutyrate (BHB) levels in alleviating T2DM. Nevertheless, the 
      role of BHB has not been clearly elucidated. METHODS: We performed a spectral 
      study to visualize the preventive effects of BHB on blood and multiorgan 
      mitochondrial redox imbalance in T2DM mice via using label-free resonance Raman 
      spectroscopy (RRS), and further explored the impact of BHB therapy on the 
      pathology of T2DM mice by histological and biochemical analyses. FINDINGS: Our 
      data revealed that RRS-based mitochondrial redox states assay enabled clear and 
      reliable identification of the improvement of mitochondrial redox imbalance by 
      BHB, evidenced by the reduction of Raman peak intensity at 750 cm(-1), 
      1128 cm(-1) and 1585 cm(-1) in blood, tissue as well as purified mitochondria of 
      db/db mice and the increase of tissue mitochondrial succinic dehydrogenase (SDH) 
      staining after BHB treatment. Exogenous supplementation of BHB was also found to 
      attenuate T2DM pathology related to mitochondrial redox states, involving organ 
      injury, blood glucose control, insulin resistance and systemic inflammation. 
      INTERPRETATION: Our findings provide strong evidence for BHB as a potential 
      therapeutic strategy targeting mitochondria for T2DM.
CI  - Copyright (c) 2024 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Wang, Na
AU  - Wang N
AD  - Taizhou Hospital, Zhejiang University School of Medicine, Linhai, China; Key 
      Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of Digestive 
      System Tumor of Zhejiang Province, Taizhou Hospital of Zhejiang Province 
      Affiliated to Wenzhou Medical University, Linhai, China.
FAU - Yang, Anqi
AU  - Yang A
AD  - Centre for Optical and Electromagnetic Research, National Engineering Research 
      Center for Optical Instruments, Zhejiang Provincial Key Laboratory for Sensing 
      Technologies, Zhejiang University, Hangzhou 310058, China.
FAU - Tian, Xiong
AU  - Tian X
AD  - Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of 
      Digestive System Tumor of Zhejiang Province, Taizhou Hospital of Zhejiang 
      Province Affiliated to Wenzhou Medical University, Linhai, China.
FAU - Liao, Jiaqi
AU  - Liao J
AD  - Centre for Optical and Electromagnetic Research, National Engineering Research 
      Center for Optical Instruments, Zhejiang Provincial Key Laboratory for Sensing 
      Technologies, Zhejiang University, Hangzhou 310058, China.
FAU - Yang, Zhenyu
AU  - Yang Z
AD  - Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of 
      Digestive System Tumor of Zhejiang Province, Taizhou Hospital of Zhejiang 
      Province Affiliated to Wenzhou Medical University, Linhai, China.
FAU - Pan, Yixiao
AU  - Pan Y
AD  - Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of 
      Digestive System Tumor of Zhejiang Province, Taizhou Hospital of Zhejiang 
      Province Affiliated to Wenzhou Medical University, Linhai, China.
FAU - Guo, Yiqing
AU  - Guo Y
AD  - Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of 
      Digestive System Tumor of Zhejiang Province, Taizhou Hospital of Zhejiang 
      Province Affiliated to Wenzhou Medical University, Linhai, China.
FAU - He, Sailing
AU  - He S
AD  - Taizhou Hospital, Zhejiang University School of Medicine, Linhai, China; Centre 
      for Optical and Electromagnetic Research, National Engineering Research Center 
      for Optical Instruments, Zhejiang Provincial Key Laboratory for Sensing 
      Technologies, Zhejiang University, Hangzhou 310058, China; School of Electrical 
      Engineering, Royal Institute of Technology, Stockholm S-100 44, Sweden. 
      Electronic address: sailing@kth.se.
LA  - eng
PT  - Journal Article
DEP - 20240222
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - TZP1275679 (3-Hydroxybutyric Acid)
SB  - IM
MH  - Mice
MH  - Animals
MH  - *Diabetes Mellitus, Experimental
MH  - Spectrum Analysis, Raman
MH  - 3-Hydroxybutyric Acid/pharmacology
MH  - Mitochondria
MH  - Oxidation-Reduction
MH  - *Diabetes Mellitus, Type 2/drug therapy
OTO - NOTNLM
OT  - Label-free
OT  - Mitochondrial redox state
OT  - Raman spectroscopy
OT  - Type 2 diabetes
OT  - beta-hydroxybutyric acid
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/02/23 00:42
MHDA- 2024/03/04 06:42
CRDT- 2024/02/22 18:02
PHST- 2023/12/23 00:00 [received]
PHST- 2024/02/08 00:00 [revised]
PHST- 2024/02/19 00:00 [accepted]
PHST- 2024/03/04 06:42 [medline]
PHST- 2024/02/23 00:42 [pubmed]
PHST- 2024/02/22 18:02 [entrez]
AID - S0753-3322(24)00201-4 [pii]
AID - 10.1016/j.biopha.2024.116320 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2024 Mar;172:116320. doi: 10.1016/j.biopha.2024.116320. Epub 
      2024 Feb 22.